Erectile dysfunction refers to the inability of men to sustain or maintain sufficient penile erection to complete satisfactory sexual intercourse. The overall prevalence of erectile dysfunction (ED) in men in our country is 26.1%, with the highest incidence among individuals aged 30 to 50, reaching 40.2% in the population over 40 years old.
Currently, there are five approved PDE-5 inhibitors in our country, namely sildenafil, vardenafil, tadalafil, avanafil, and udenafil.
About 90% of ED patients in our country are treated with medication, leading to a high demand for ED drugs. It is projected that by 2023, retail sales of ED drugs in China will increase by 5.8%.
The available drugs for treating ED in our country include PDE-5 inhibitors and androgens. Among them, PDE-5 inhibitors are the first-line drugs for treating ED in our country, widely used in clinical practice. Sildenafil, commonly known as “Viagra,” was the first PDE-5 inhibitor approved for treating ED in China, with sales of 2.735 billion yuan in public hospitals in 2022.
(Source: Goin Research Industrial Consultation)
Goin Research released a “Comprehensive Survey and Market Supply and Demand Forecast Report on the Chinese Anti-erectile Dysfunction Drug Industry 2024-2030,” consisting of twelve chapters. The report covers the definition of the anti-erectile dysfunction drug industry, business models, industry barriers, risk factors, industry characteristics, research methods, market analysis, trade situation, operational conditions analysis, industry competitive landscape, among others, providing insights into the industry dynamics.
The report outlines the development overview, market analysis, and trends in the anti-erectile dysfunction drug industry in China from 2018 to 2022. It includes production analysis, domestic enterprise production permits overview, regional distribution of production enterprises, demand analysis, product price analysis, influencing factors on product prices, development and production trends, and a market competition analysis.
(Source: Goin Research Industrial Consultation)
